LONDON, ONTARIO–(Marketwire – March 8, 2010) - Stellar Pharmaceuticals Inc. (OTCBB:SLXCF) (“Stellar” or “the Company”), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that it has been informed by the Chinese Patent Office that a patent has been allowed for one of its lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful bladder syndrome (“IC/PBS”).

Further information:

Article source

Related posts:

1. Stellar Pharmaceuticals to Present at the Cowen & Company 30th Annual Healthcare Conference
2. Rexahn Pharmaceuticals Issued Japanese Patent For Anti-cancer Compound Archexin(R)
3. Taj Pharmaceuticals Announces Issuance of US Patent for Terfenadine
4. U.S. patent office rejects part of Viagra patent
5. ALDA Receives Australian Patent for T36(R) Disinfectant